Although the preclinical efficacy of small-molecule USP7 inhibitors was demonstrated in vivo and the synergistic effect of combining USP7 inhibition with cancer immunotherapy appears promising, the field seems to be at its infancy. This evidence concerns the gene USP7 and cancer.